Will Cumberland Pharmaceuticals stock go up?

According to Danelfin AI, Cumberland Pharmaceuticals has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (49.50%) is -1.31% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Cumberland Pharmaceuticals stock?

The Cumberland Pharmaceuticals target price is $10.33 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Cumberland Pharmaceuticals stock right now?

Cumberland Pharmaceuticals has today a Hold rating (AI Score 4/10), according to Danelfin AI. Its probability of beating the market in 3 months (49.50%) is -1.31% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Cumberland Pharmaceuticals stock is a good buy .

Is Cumberland Pharmaceuticals undervalued right now?

Based on analysts, the average price target upside for Cumberland Pharmaceuticals is +44.44% (1Y). According to Danelfin AI, Cumberland Pharmaceuticals has today an AI Score of 4/10 (Hold Rating).

What was the price range of Cumberland Pharmaceuticals stock over the past 12 months?

The Cumberland Pharmaceuticals stock price range over the past 12 months has been $1.9 - $7.15.

What is going on with Cumberland Pharmaceuticals stock in the last 3 months?

The Cumberland Pharmaceuticals stock performance in the last quarter has been +120.00%.

Does Cumberland Pharmaceuticals offer dividend payments?

No, Cumberland Pharmaceuticals does not currently pay dividends.

What is the current market capitalization of Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals's market cap is $106.83M, as of 2026-07-02 08:00.

When is the next CPIX earnings report date?

CPIX will publish its next earnings report on 2026-05-05.

Cumberland Pharmaceuticals Inc (CPIX) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

CPIX AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Cumberland Pharmaceuticals Inc today receives an AI Score of 4/10, which translates to a Hold rating. The stock has a 50% probability of outperforming the market in the next 3 months, which is 1% lower than the average probability of any stock (51%). Among the top positive contributors, the Fundamentals Impact (Long Tail) boosts the probability by +0.68%, the Technicals Impact (Long Tail) adds +0.51%, and the Pharmaceuticals industry contributes +0.50%. On the negative side, the Fear & Greed Index detracts -0.58%, Beginning Cash (bottom 20%) reduces probability by -0.57%, and Gross Margin (top 20%) weighs down -0.44%. Notable data points include a Gross Margin of 78.8% (top 20%), which is typically positive but here detracts from the probability, and a Plus Directional Indicator (+DI, 90d) of 31.0 (top 10%), also a detractor. Conversely, Alpha 1Y of 0.93 (top 10%) positively influences the probability. The stock's Operating Profit Margin is -34.3% (bottom 30%), reflecting weak profitability. Overall, the mixed signals—positive long-tail fundamentals and technicals offset by negative sentiment and specific financial weaknesses—result in a Hold rating, suggesting the stock is expected to perform in line with the market.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Earnings Quality+0.19%
Stability and reliability of reported earnings
Valuation+0.06%
How the stock is priced relative to its fundamentals
Sentiment0.00%
How analysts and the market view the stock

Profitability-0.64%
Profitability and operating efficiency metrics
Size & Liquidity-0.57%
Company size and trading liquidity
Momentum-0.21%
Direction and strength of recent price movements
Volatility-0.14%
How much the stock price tends to fluctuate

CPIX probability advantage of beating the market (3M):

-1.32%

AI Score

Hold

Cumberland Pharmaceuticals (CPIX) has an AI Score of 4/10 (Hold) because, according to an overall analysis, it has a probability advantage of -1.31% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of CPIX (49.50%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
CPIX probability advantage of beating the market (3M)-1.31%
CPIX probability of beating the market (3M)49.50%

CPIX probability advantage of beating the market (3M): -1.31%

The AI-powered overall analysis of Cumberland Pharmaceuticals (CPIX) is based on the 24 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of CPIX:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+0.68%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.58%
Fundamental	Beginning Cash (Millions)	11.44		-0.57%
Technical	Technicals Impact (Long Tail)	-	N/A	+0.51%
Sentiment	Industry (GICS)	Pharmaceuticals	N/A	+0.50%
Fundamental	Gross Margin	78.82		-0.44%
Technical	Chart Pattern (504d)	figure_98	N/A	-0.39%
Technical	Plus Directional Indicator (+DI, 90d)	30.98%		-0.32%
Fundamental	Tangible Shareholders' Equity	7.6		-0.27%
Sentiment	Sentiment Impact (Long Tail)	-	N/A	+0.25%
Technical	Upgrade to unlock			-0.24%
Sentiment	Upgrade to unlock			+0.21%
Fundamental	Upgrade to unlock			-0.21%
Fundamental	Upgrade to unlock			-0.20%
Technical	Upgrade to unlock			-0.20%

Rest of Alpha Signals: -0.04%

CPIX probability advantage of beating the market (3M)Total:-1.31%
CPIX AI Score

Significant changes Vs previous day

CPIX Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$7.15
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

CPIX Proven Hold Signal & Price Forecast

This is the price chart for CPIX from January 2, 2026 until today. The chart indicates, in yellow, the 112 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

CPIX Average Past Performance & Win Rate

Three months after its 1505 Hold signals since July 2026, CPIX had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

1505 Past CPIX Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+3.77%
Average Alpha				-10.55%
Win Rate (% Positive Perf.)				24.11%
% Positive Alpha				20.08%

CPIX Frequently Asked Questions

Will Cumberland Pharmaceuticals stock go up?
According to Danelfin AI, Cumberland Pharmaceuticals has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (49.50%) is -1.31% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Cumberland Pharmaceuticals stock?
Is it a good time to buy, sell, or hold Cumberland Pharmaceuticals stock right now?
Is Cumberland Pharmaceuticals undervalued right now?
What was the price range of Cumberland Pharmaceuticals stock over the past 12 months?
What is going on with Cumberland Pharmaceuticals stock in the last 3 months?
Does Cumberland Pharmaceuticals offer dividend payments?
What is the current market capitalization of Cumberland Pharmaceuticals?
When is the next CPIX earnings report date?

Cumberland Pharmaceuticals Inc Company Profile

Cumberland Pharmaceuticals Inc. operates as a specialty pharmaceutical corporation with an emphasis on procuring, cultivating, and bringing to market prescription medicine used in hospital acute care, gastroenterology, and oncology in the U.S. and across the globe. The company provides several distinct products including Acetadote, an injection administered for acetaminophen poisoning cases; Caldolor captures the market for pain and fever relief; Kristalose is included for constipation treatment plans owing to its properties as a prescription laxative oral solution.

Additionally, Omeclamox-Pak functions as a remedy for Helicobacter pylori infection along with duodenal ulcer conditions while Vaprisol is available as an injection to balance out euvolemic and hypervolemic hyponatremia cases. Sancuso injectable serves chemotherapy patients whereas Vibativ brings relief amidst certain severe bacterial infections that encompass hospital-acquired pneumonia, ventilator-associated bacterial pneumonia along with intricate skin structure infections.

The pharmaceutical firm is also underway in terms of developing RediTrex which acts as decisive treatment against active rheumatoid, juvenile idiopathic arthritis including formidable psoriasis cases. Furthermore, Cumberland has ventured into creating ifetroban—a product under phase II clinical tests designed to cure aspirin-exacerbated respiratory disorder plus systemic sclerosis notwithstanding duchenne muscular dystrophy.

Apart from having finished phase II tests for treating hepatorenal syndrome alongside portal hypertension issues—there's also progressive development in regard to devising clinical programs centered around utilizing ifetroban for addressing progressive fibrosing interstitial lung diseases. The roots of this progressively innovative company trace back to 1999 when it was established—it currently stations its headquarters in Nashville, Tennessee.

Sector:Health Care
Country:United States
Industry:Pharmaceuticals
Address:1600 West End Avenue, Suite 1300, Nashville
Employees:93
Website:cumberlandpharma.com

Pros

Established portfolio of commercialized pharmaceutical products

Intellectual property protection for proprietary formulations

Specialized distribution network for hospital-based therapies

Operating leverage from existing manufacturing infrastructure

Potential for inorganic growth through product acquisitions

Cons

Revenue dependency on a narrow product offering

Vulnerability to patent expiration and generic entry

High regulatory approval risk for pipeline assets

Exposure to pharmaceutical pricing pressure from payers

Capital requirements for clinical development programs

Company	AI Score	Compare
PPBTPurple Biotech Ltd
LGNDLigand Pharmaceuticals Inc
CVKDCadrenal Therapeutics Inc
COLLCollegium Pharmaceutical Inc
CBIOCrescent Biopharma Inc

Company	AI Score	Compare
PPBTPurple Biotech Ltd
LGNDLigand Pharmaceuticals Inc
CVKDCadrenal Therapeutics Inc
COLLCollegium Pharmaceutical Inc
CBIOCrescent Biopharma Inc

CPIX Stock AI Analysis